Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross‐national descriptive study from the PROTECT‐EU Project

Studies on drug utilization usually do not allow direct cross‐national comparisons because of differences in the respective applied methods. This study aimed to compare time trends in BZDs prescribing by applying a common protocol and analyses plan in seven European electronic healthcare databases.

[1]  E. Roughead,et al.  The validity of the Rx-Risk Comorbidity Index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) Classification System , 2018, BMJ Open.

[2]  J. Hasford,et al.  Bridging Differences in Outcomes of Pharmacoepidemiological Studies: Design and First Results of the PROTECT Project , 2014, Current clinical pharmacology.

[3]  J. Hallas,et al.  Primary non-adherence in general practice: a Danish register study , 2014, European Journal of Clinical Pharmacology.

[4]  G. Glaeske,et al.  Benzodiazepinhypnotika, Zolpidem und Zopiclon auf Privatrezept , 2014, Der Nervenarzt.

[5]  F. Hoffmann.  Benefits and risks of benzodiazepines and Z-drugs: comparison of perceptions of GPs and community pharmacists in Germany , 2013, German medical science : GMS e-journal.

[6]  K. Jordan,et al.  The relationship of primary health care use with persistence of insomnia: a prospective cohort study , 2012, BMC Family Practice.

[7]  S. Greenland,et al.  Risk of Fractures Requiring Hospitalization After an Initial Prescription for Zolpidem, Alprazolam, Lorazepam, or Diazepam in Older Adults , 2011, Journal of the American Geriatrics Society.

[8]  A. Beekman,et al.  Ten-year trends in benzodiazepine use in the Dutch population , 2011, Social Psychiatry and Psychiatric Epidemiology.

[9]  G. Glaeske,et al.  Regional variations of private prescriptions for the non‐benzodiazepine hypnotics zolpidem and zopiclone in Germany , 2010, Pharmacoepidemiology and drug safety.

[10]  Sven Schmiedl,et al.  Potentially inappropriate medications in the elderly: the PRISCUS list. , 2010, Deutsches Arzteblatt international.

[11]  F. Keller,et al.  Psychotropic medication in children and adolescents in Germany: prevalence, indications, and psychopathological patterns. , 2009, Journal of child and adolescent psychopharmacology.

[12]  S. Hunskaar,et al.  Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Database , 2009, Pharmacoepidemiology and drug safety.

[13]  M. Ashworth,et al.  Variations in anxiolytic and hypnotic prescribing by GPs: a cross-sectional analysis using data from the UK Quality and Outcomes Framework. , 2009, The British journal of general practice : the journal of the Royal College of General Practitioners.

[14]  R. de Graaf,et al.  Are attitudes towards mental health help-seeking associated with service use? Results from the European Study of Epidemiology of Mental Disorders , 2009, Social Psychiatry and Psychiatric Epidemiology.

[15]  Y. Hsia,et al.  Rise in psychotropic drug prescribing in children and adolescents during 1992–2001: a population-based study in the UK , 2009, European Journal of Epidemiology.

[16]  L. Merle,et al.  Inappropriate Medications in the Elderly , 2009, Clinical pharmacology and therapeutics.

[17]  G. Glaeske,et al.  A three-country comparison of psychotropic medication prevalence in youth , 2008, Child and adolescent psychiatry and mental health.

[18]  J. Haro,et al.  Clinical factors influencing the prescription of antidepressants and benzodiazepines: results from the European study of the epidemiology of mental disorders (ESEMeD). , 2008, Journal of affective disorders.

[19]  M. Jansson-Fröjmark,et al.  A bidirectional relationship between anxiety and depression, and insomnia? A prospective study in the general population. , 2008, Journal of psychosomatic research.

[20]  R. Amrein,et al.  Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies , 2007, International clinical psychopharmacology.

[21]  L. Merle,et al.  Potentially inappropriate medications in the elderly: a French consensus panel list , 2007, European Journal of Clinical Pharmacology.

[22]  F. D. A. Iglesias,et al.  Utilización de ansiolíticos e hipnóticos en España (1995-2002) , 2004 .

[23]  M. Beers,et al.  Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. , 2003, Archives of internal medicine.

[24]  M. Ohayon,et al.  Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. , 2002, The Journal of clinical psychiatry.

[25]  F. Zitman,et al.  Different study criteria affect the prevalence of benzodiazepine use , 2002, Social Psychiatry and Psychiatric Epidemiology.

[26]  Bill Hunter,et al.  European Commission , 1992, The International Encyclopedia of Higher Education Systems and Institutions.

[27]  J. Paty,et al.  Are prescribed medications effective in the treatment of insomnia complaints? , 1999, Journal of psychosomatic research.

[28]  Y. Lecrubier,et al.  The prescribing of psychotropic drugs by primary care physicians: an international collaborative study. , 1999, Journal of clinical psychopharmacology.

[29]  Albert Bakker,et al.  Usage patterns of benzodiazepines in a Dutch community: a 10‐year follow‐up. , 1998, Pharmacy World and Science.

[30]  C. Guilleminault,et al.  Psychotropic medication consumption patterns in the UK general population. , 1998, Journal of clinical epidemiology.

[31]  M. Beers,et al.  Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. , 1997, Archives of internal medicine.

[32]  R. Tamblyn,et al.  Defining inappropriate practices in prescribing for elderly people: a national consensus panel. , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[33]  D. Melzer,et al.  Variation in prescribing of hypnotics, anxiolytics and antidepressants between 61 general practices. , 1995, The British journal of general practice : the journal of the Royal College of General Practitioners.

[34]  M. Foets,et al.  Sex differences among recipients of benzodiazepines in Dutch general practice. , 1993, BMJ.

[35]  F. E. Shideman.  Hypnotics and sedatives. , 1958, Postgraduate medicine.

[36]  Canary Wharf,et al.  The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) , 2012 .

[37]  G. Zammit.  Comparative Tolerability of Newer Agents for Insomnia , 2009, Drug safety.

[38]  Katharina Wirtz,et al.  Data Warehousing for Bavarian Out-Patient Public Health Care , 2006, ECEH.

[39]  H. Leufkens,et al.  Comparing patterns of long‐term benzodiazepine use between a Dutch and a Swedish community , 2003, Pharmacoepidemiology and drug safety.

[40]  J. G. D. Pozo,et al.  Utilización de ansiolíticos e hipnóticos en España , 2002 .